Literature DB >> 14689222

Predictive medicine in non-malignant urological disorders.

Mariangela Mancini1, Antonio Cisternino, Ivan Matteo Tavolini, Fabrizio Dal Moro, Pierfrancesco Bassi.   

Abstract

The potential of disease prediction in non-malignant disorders should not be undervalued. Such disorders present several characteristics which make them suitable for disease prediction: they can be wide-spread, strongly affect the patients' quality of life, lead to a heavy burden on social health expenses and have a protracted clinical course. Moreover, people who present a high risk for non-malignant disease can be successfully introduced to long-term preventive measures such as lifestyle modifications, dietary changes and improvement in hygienic conditions. There is a growing demand for developing predictive medical strategies in urology. While urological cancers are the main focus of interest, we analyse the potentialities and challenges of predictive medicine in non-malignant urological disorders, with particular attention to benign prostate hyperplasia and urolithiasis.

Entities:  

Mesh:

Year:  2003        PMID: 14689222     DOI: 10.1007/s00345-003-0381-9

Source DB:  PubMed          Journal:  World J Urol        ISSN: 0724-4983            Impact factor:   4.226


  90 in total

1.  Complication of the sacral neuromodulator: lead avulsion and wire disruption.

Authors:  Ananias C Diokno; Scott Burgess; Timothy Mulholland
Journal:  J Urol       Date:  2003-01       Impact factor: 7.450

2.  BCL2 protein is topographically restricted in tissues characterized by apoptotic cell death.

Authors:  D M Hockenbery; M Zutter; W Hickey; M Nahm; S J Korsmeyer
Journal:  Proc Natl Acad Sci U S A       Date:  1991-08-15       Impact factor: 11.205

3.  Serum prostate specific antigen is a strong predictor of future prostate growth in men with benign prostatic hyperplasia. PROSCAR long-term efficacy and safety study.

Authors:  C G Roehrborn; J McConnell; J Bonilla; S Rosenblatt; P B Hudson; G H Malek; P F Schellhammer; R Bruskewitz; A M Matsumoto; L H Harrison; H A Fuselier; P Walsh; J Roy; G Andriole; M Resnick; J Waldstreicher
Journal:  J Urol       Date:  2000-01       Impact factor: 7.450

4.  Meta-analysis of randomized trials for medical prevention of calcium oxalate nephrolithiasis.

Authors:  M S Pearle; C G Roehrborn; C Y Pak
Journal:  J Endourol       Date:  1999-11       Impact factor: 2.942

5.  Clinical and biological characteristics of familial benign prostatic hyperplasia.

Authors:  M G Sanda; C B Doehring; B Binkowitz; T H Beaty; A W Partin; E Hale; E Stoner; P C Walsh
Journal:  J Urol       Date:  1997-03       Impact factor: 7.450

Review 6.  Mechanisms mediating oxalate-induced alterations in renal cell functions.

Authors:  Julie A Jonassen; Lu-Cheng Cao; Thomas Honeyman; Cheryl R Scheid
Journal:  Crit Rev Eukaryot Gene Expr       Date:  2003       Impact factor: 1.807

7.  The effects of twelve weeks of bed rest on bone histology, biochemical markers of bone turnover, and calcium homeostasis in eleven normal subjects.

Authors:  J E Zerwekh; L A Ruml; F Gottschalk; C Y Pak
Journal:  J Bone Miner Res       Date:  1998-10       Impact factor: 6.741

Review 8.  CSE1L/CAS: its role in proliferation and apoptosis.

Authors:  P Behrens; U Brinkmann; A Wellmann
Journal:  Apoptosis       Date:  2003-01       Impact factor: 4.677

9.  Association of vitamin D receptor gene polymorphism with urolithiasis.

Authors:  Saori Nishijima; Kimio Sugaya; Ayako Naito; Makoto Morozumi; Tadashi Hatano; Yoshihide Ogawa
Journal:  J Urol       Date:  2002-05       Impact factor: 7.450

10.  Sequential reduction of mitochondrial transmembrane potential and generation of reactive oxygen species in early programmed cell death.

Authors:  N Zamzami; P Marchetti; M Castedo; D Decaudin; A Macho; T Hirsch; S A Susin; P X Petit; B Mignotte; G Kroemer
Journal:  J Exp Med       Date:  1995-08-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.